Condition
Hypersensitivity Reactions
Total Trials
5
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 1 (1)
P 3 (1)
Trial Status
Completed2
Not Yet Recruiting2
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT03598426Phase 3CompletedPrimary
Conventional Prophylactic Oral Dexamethasone vs Short-course IV Dexamethasone in Paclitaxel Hypersensitivity
NCT07605806Phase 1Recruiting
Novel Biomarkers of Non-IgE Immediate Hypersensitivity Drug Reactions
NCT07573202Not ApplicableNot Yet RecruitingPrimary
Evaluation of Hypersensitivity Reactions to Silk Fibroin Versus 2-octyl Cyanoacrylate Mesh in Shoulder Surgery
NCT07572162Not Yet RecruitingPrimary
Post-market Safety Study of LUMISIGHT
NCT04359368Completed
Characteristics of Patients With Hypersensitivity Reactions to Intravenous Iron Infusions
Showing all 5 trials